Skip to main content

tooluniverse-structural-proteomics

Structural biology plus proteomics integration for drug target validation. Combines PDB experimental structures, AlphaFold predictions, GPCRdb, SAbDab antibody structures, ProteinsPlus binding-site prediction, and BindingDB ligand-affinity data. Use for druggability assessment, binding-site characterization, ligand-pocket analysis, structural-confidence scoring (resolution, pLDDT), and antibody-target interface analysis.

الانتقال إلى التثبيت

معلومات المصدر

المستودع
mims-harvard/ToolUniverse
آخر نشاط في المصدر
١٦ سبتمبر ٢٠٢٦ في ٠٥:١٤
لغة SKILL.md المكتشفة
الإنجليزية
النجوم
١٬٧٠٥
التفرعات
٢٥٨

خيارات التثبيت

يُحدَّد Prompt الذي يراجع المصدر أولًا بشكل افتراضي. يمكنك التبديل إلى أمر مباشر أو تنزيل نسخة محلية.

مراجعة ملفات المصدر

اقرأ SKILL.md وأي ملفات مرافقة يعرضها SkillsMP قبل أن تقرر التثبيت.

عرض SKILL.md

SKILL.md
تعليمات المصدر · معاينة للقراءة فقط
name
tooluniverse-structural-proteomics
description
Structural biology plus proteomics integration for drug target validation. Combines PDB experimental structures, AlphaFold predictions, GPCRdb, SAbDab antibody structures, ProteinsPlus binding-site prediction, and BindingDB ligand-affinity data. Use for druggability assessment, binding-site characterization, ligand-pocket analysis, structural-confidence scoring (resolution, pLDDT), and antibody-target interface analysis.
disable-model-invocation
true
# Structural Proteomics for Drug Target Validation Comprehensive structural data integration using ToolUniverse tools across PDB, AlphaFold, GPCRdb, SAbDab, and proteomics databases for drug target validation. ## LOOK UP DON'T GUESS - PDB structures/resolutions: `PDBeSIFTS_get_best_structures` and `RCSBGraphQL_get_structure_summary` - AlphaFold confidence: `alphafold_get_summary` - Ligands/affinities: `PDBe_get_structure_ligands` and `BindingDB_get_ligands_by_uniprot` - Protein-protein binding mutations (ddG): `SKEMPI_search_by_structure`/`SKEMPI_search_by_protein`/`SKEMPI_get_mutation` -- BindingDB's protein-protein equivalent, for interface-mutation affinity effects rather than small-molecule ligands - Druggability: `ProteinsPlus_predict_binding_sites` ## COMPUTE, DON'T DESCRIBE When analysis requires computation (statistics, data processing, scoring, enrichment), write and run Python code via Bash. Don't describe what you would do — execute it and report actual results. Use ToolUniverse tools to retrieve data, then Python (pandas, scipy, statsmodels, matplotlib) to analyze it. ## Domain Reasoning Resolution determines valid conclusions: <2A = atom positions visible; 2-3A = side chains reliable, drug design supported; >3A = backbone only, binding site unreliable. Do not over-interpret low-resolution structures. --- ## Tool Inventory ### PDB (RCSB) `RCSBAdvSearch_search_structures` (query_type, query_value, rows), `RCSBData_get_entry` (entry_id), `RCSBGraphQL_get_structure_summary` (pdb_id), `RCSBGraphQL_get_ligand_info` (pdb_id), `RCSB_get_chemical_component` (comp_id) ### PDB (PDBe) `pdbe_get_entry_summary` (pdb_id), `PDBe_get_structure_ligands` (pdb_id), `PDBe_get_bound_molecules` (pdb_id), `PDBeSearch_search_structures` (query, rows), `PDBeSIFTS_get_best_structures` (uniprot_id), `PDBeSIFTS_get_all_structures` (uniprot_id), `PDBe_KB_get_ligand_sites` (pdb_id), `PDBe_KB_get_interface_residues` (pdb_id), `PDBeValidation_get_quality_scores` (pdb_id) ### PDBe PISA `PDBePISA_get_interfaces` (pdb_id), `PDBePISA_get_assemblies` (pdb_id) ### AlphaFold `alphafold_get_prediction` (qualifier=UniProt), `alphafold_get_summary` (qualifier), `alphafold_get_annotations` (qualifier) ### Binding Sites `ProteinsPlus_predict_binding_sites` (pdb_id, chain), `BindingDB_get_ligands_by_uniprot` (uniprot_id), `BindingDB_get_ligands_by_pdb` (pdb_id), `BindingDB_get_targets_by_compound` (smiles) ### Foldseek `Foldseek_search_structure` (sequence, mode="tmalign"), `Foldseek_get_result` (ticket) ### GPCRdb `GPCRdb_get_protein` (protein), `GPCRdb_get_structures` (protein), `GPCRdb_get_ligands` (protein), `GPCRdb_get_mutations` (protein). Accepts entry names, gene symbols (auto-converted to `{symbol.lower()}_human`), or UniProt accessions. ### SAbDab `SAbDab_search_structures` (query/antigen), `SAbDab_get_structure` (pdb_id), `TheraSAbDab_search_therapeutics` (query), `TheraSAbDab_search_by_target` (target) ### Domains `InterPro_get_protein_domains` (uniprot_id), `Pfam_get_protein_annotations` (uniprot_id), `UniProt_get_entry_by_accession` (accession) ### Proteomics `ProteomeXchange_search_datasets` (query), `ProteomeXchange_get_dataset` (dataset_id) --- ## Workflow 1: Find All Structures for a Drug Target ``` Phase 0: Resolve protein → UniProt ID, gene symbol, organism Phase 1: PDBeSIFTS_get_best_structures → RCSBGraphQL_get_structure_summary → PDBeValidation Phase 2: alphafold_get_prediction/summary → compare pLDDT with experimental coverage Phase 3: IF GPCR → GPCRdb; IF antibody target → SAbDab/TheraSAbDab Phase 4: InterPro/Pfam domain mapping → identify unresolved regions Phase 5: Summary table (PDB ID, method, resolution, ligands, coverage, quality) ``` **Decisions**: Resolution <2.5A for drug design. X-ray > Cryo-EM > NMR > AlphaFold for binding sites. Holo > apo structures. ## Workflow 2: Identify Binding Pocket Ligands ``` Phase 1: PDBe_get_structure_ligands + RCSBGraphQL_get_ligand_info + PDBe_KB_get_ligand_sites Phase 2: ProteinsPlus_predict_binding_sites → druggability score, pocket residues Phase 3: BindingDB_get_ligands_by_pdb/uniprot → Ki, Kd, IC50 Phase 4: RCSB_get_chemical_component for key ligands ``` **Filter artifacts**: GOL, EDO, SO4, PEG, ACT, CL, NA. Keep cofactors (ATP, NAD, HEM) and catalytic metals (ZN, MG) if relevant. ## Workflow 3: Cross-Validate Drug Binding ``` Phase 1: Find co-crystal structures → filter for drug/analogs Phase 2: BindingDB affinity data (Ki, Kd, IC50) Phase 3: ProteinsPlus + PDBe-KB binding site characterization Phase 4: PDBeValidation quality → binding site well-resolved? Phase 5: AlphaFold + Foldseek structural comparison Phase 6: GPCR-specific (if applicable) → active/inactive states, pharmacology, resistance mutations Phase 7: Antibody-specific (if applicable) → epitope mapping Phase 8: Evidence integration ``` --- ## Tool Parameter Gotchas | Tool | Mistake | Correct | |------|---------|---------| | `alphafold_get_prediction/summary` | `uniprot_id` | `qualifier` | | `GPCRdb_get_protein` | `gene_name` | `protein` | | `PDBeSIFTS_get_best_structures` | gene symbol | `uniprot_id` (e.g., "P04637") | | `Foldseek_search_structure` | `mode="3diaa"` | `mode="tmalign"` | | `SAbDab_search_structures` | `name` | `query` or `antigen` | | `RCSB_get_chemical_component` | `ligand_id` | `comp_id` | --- ## Evidence Grading | Tier | Confidence | |------|------------| | T1 | Co-crystal (<2.5A) + binding affinity data | | T2 | Experimental structure + computational prediction | | T3 | AlphaFold + pocket analysis + known ligand analogs | | T4 | Homology model or low-resolution only | ## Interpretation | Metric | High | Acceptable | Caution | |--------|------|-----------|---------| | Resolution | <2.0A (X-ray) / <3.0A (cryo-EM) | 2.0-2.5A / 3.0-4.0A | >3.0A / >4.5A | | R-free | <0.25 | 0.25-0.30 | >0.30 | | AlphaFold pLDDT | >90 | 70-90 | <70 (disordered) | DoGSiteScorer >0.6 = druggable; <0.4 = unlikely druggable. PISA assemblies should be cross-validated with SEC-MALS/native MS. ## Limitations - BindingDB: 60s+ for popular targets - AlphaFold: lacks ligand context - GPCRdb: Class A-F GPCRs only - PDBePISA: `operation` is internal, not a public parameter
عرض على GitHub